[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Zappa L, Godwin TA, Sugarbaker PH: Tailgut cyst, an unusual cause of pseudomyxoma peritonei. Tumori; 2009 Jul-Aug;95(4):514-7
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst, an unusual cause of pseudomyxoma peritonei.
  • The tumor occurs in the retrorectal space and may undergo malignant degeneration.
  • METHODS: The clinical information on a single patient with pseudomyxoma peritonei associated with a tailgut cyst was reviewed and a literature review of the subject performed.
  • RESULTS: In this patient there was malignant degeneration of a tailgut cyst localized to the pelvis.
  • Twenty months later a local recurrence in the pelvis and pseudomyxoma peritonei widely distributed in the abdomen were successfully treated by cytoreductive surgery and perioperative chemotherapy.
  • CONCLUSION; Tailgut cyst may, if resected with tumor spillage, result in pseudomyxoma peritonei.
  • Our treatment--which has maintained a disease-free status for one year--was cytoreductive surgery plus perioperative chemotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Hamartoma / complications. Neoplasms, Multiple Primary / complications. Peritoneal Neoplasms / complications. Pseudomyxoma Peritonei / complications. Rectal Diseases / complications
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856666.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Li C, Kanthan R, Kanthan SC: Pseudomyxoma peritonei--a revisit: report of 2 cases and literature review. World J Surg Oncol; 2006;4:60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei--a revisit: report of 2 cases and literature review.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare, chronic, relapsing, diagnostically challenging and poorly understood disease characterized by disseminated mucinous ascites and peritoneal implants.
  • CASE PRESENTATION: We report two cases of PMP that represent the two biological variants of disseminated peritoneal adenomucinosis (DPAM)--the benign variant and the peritoneal mucinous carcinomatosis (PMCA)--the malignant variant, both of which were characterized by multiple relapses and progression of the disease despite aggressive management.
  • CONCLUSION: Even with a better understanding and recent advances in the management of these cases, PMP remains an enigmatic disease with a protracted clinical course characterized by multiple recurrences despite surgery and/or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):571-8 [12717243.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):1-9 [8986525.001]
  • [Cites] Cancer Treat Res. 1996;81:121-32 [8834580.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):441-7 [8211593.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):680-4 [16571440.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):382-6 [15932563.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] J Surg Oncol. 2004 Sep 15;87(4):162-6 [15334630.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] World J Surg Oncol. 2004;2:19 [15180896.001]
  • (PMID = 16945158.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574320
  •  go-up   go-down


3. Yan TD, Stuart OA, Yoo D, Sugarbaker PH: Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med; 2006;4:17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy.
  • The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination from gastrointestinal and ovarian cancers.
  • Cancer progression causes peritoneal implants to be distributed throughout the abdominopelvic cavity.
  • In the past, the prognosis of patients with peritoneal surface malignancy was regarded dismal and cure was not an option.
  • Recently, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an improved survival in selected patients with this disease.
  • To date, multiple different treatment regimens of perioperative intraperitoneal chemotherapy have been used.
  • This review focuses on the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Surg. 1999 Jan-Mar;84(1):60-6 [10421021.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):58-65 [10618606.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):286-90 [11373107.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] World J Surg. 2001 Aug;25(8):985-90 [11571980.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Am J Surg. 2002 May;183(5):529-32 [12034386.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):261-5 [12657237.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):463-8 [12734097.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):755-69, xiv [14567029.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):771-80 [14567030.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):233-48 [14648781.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41 [14764027.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2727-30 [15309728.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):77-9 [16394306.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):686-91 [16621431.001]
  • [Cites] Cancer Treat Res. 1991;55:277-284 [1681861.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1252-8 [1737387.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5790-4 [2118420.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Pharmacology. 1978;17(6):330-40 [32560.001]
  • [Cites] Cancer Chemother Pharmacol. 1983;11(1):1-4 [6883622.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):450-4; discussion 455 [7639005.001]
  • [Cites] Biochem Pharmacol. 1993 Oct 5;46(7):1229-37 [8216374.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):517-23 [8420671.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2264-8 [87263.001]
  • [Cites] Cancer Treat Res. 1996;81:7-14 [8834571.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):596-603 [8862729.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(2):147-54 [9443628.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2532-40 [10375099.001]
  • [Cites] Int J Hyperthermia. 1999 Mar-Apr;15(2):79-107 [10323618.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Aug;290(2):871-80 [10411604.001]
  • (PMID = 16606461.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1481500
  •  go-up   go-down


Advertisement
4. Song ZQ, Wang WZ, Lu XH, Ke MY, Sun XH, Cui QC: [The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei]. Zhonghua Nei Ke Za Zhi; 2005 Dec;44(12):894-7
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment measures and prognosis of pseudomyxoma peritonei (PMP).
  • Positive results were often found in the assistant examinations such as erythrocyte sedimentation rate, gastrointestinal tumor markers (carcinoembryonic antigen, carcinomatous antigen 19-9 and so on), imaging (B ultrasound and computer tomography) and abdominal paracentesis which was usually unsuccessful.
  • The most frequently practiced approach is debulking surgery with the main assistant means of chemotherapy which was lack of the uniform rationale.
  • Benign type of pathological samples accounts for 66.7% of all, while mid-type 21.2% and malignant 12.1%.
  • The general median survival time is 70 months with a follow-up rate of 79%.
  • The pathological type and chemotherapy are main factors which influence the cumulative survival rate (P < 0.05).
  • The existing treatment measures need to be improved further.
  • The pathological type and chemotherapy are main factors which influence the prognosis.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409722.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Galani E, Marx GM, Steer CB, Culora G, Harper PG: Pseudomyxoma peritonei: the 'controversial' disease. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):413-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei: the 'controversial' disease.
  • Pseudomyxoma peritonei (PMP) is a rare disease that is characterized by a large amount of mucinous ascites with peritoneal and omental implants.
  • Histologically, two main categories have been described: disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA).
  • Most investigators agree that radical surgical debulking and appendectomy are the cornerstone of treatment, but the optimal management of the disease remains controversial.
  • The role of intraoperative and intraperitoneal chemotherapy has been evaluated by a number of authors.
  • The clinical outcomes vary widely between the benign and the malignant forms and between the different treatment modalities.
  • We discuss the pathology, origin, clinical presentation, diagnosis, treatment, and prognosis of PMP.
  • [MeSH-major] Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Incidence. Laparotomy / methods. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911716.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


6. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • AIMS: Pseudomyxoma peritonei may have as its primary site a mucinous gastrointestinal adenoma or carcinoma that gains access to the peritoneal cavity.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • The patients developed the characteristic pseudomyxoma peritonei syndrome.
  • All three patients were treated with cytoreductive surgery plus perioperative hyperthermic intraperitoneal chemotherapy.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • If pseudomyxoma peritonei develops, cytoreductive surgery and perioperative intraperitoneal chemotherapy should be considered for treatment.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Angelescu N, Bordea A, Popa E, Constantinescu N, Zodieru I, Mircea N: [Pseudomyxoma peritonei (gelatinous peritonitis )]. Chirurgia (Bucur); 2001 Sep-Oct;96(5):443-51
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomyxoma peritonei (gelatinous peritonitis )].
  • [Transliterated title] Pseudomixomul peritoneal (peritonita gelatinoasă).
  • Pseudomyxoma peritonei (P.P.) is characterised by the presence in the peritoneal cavity of 3 elements--mucinous neoplasic cells, mucinous ascites and diffuses mucinous implants.
  • The patients were submitted to variate surgical procedures, based on the benign (4 cases) or malignant (2 cases) character of the disease and on the origin of the lesions: cystadenoma of the appendix with secondary tumours of the ovary (the 2 females) and, respectively, cystadenoma and cytsadenocarcinoma of the appendix, mucinous paraenteric cyst with pseudomyxoma retroperitonei, mucinous recto-sigmoidian neoplasm (the 4 men).
  • We practiced intraperitoneal chemotherapy with Thio-Tepa in 5 cases (intraoperative in 4 cases) and systemic, with 5-FU and mytomicine, in one case.
  • The global 5-year survival rate was 60% (100% in the benign disease and 0% in the malignant form).
  • It was divided in two distinct forms: disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
  • The treatment associates radical surgery and intraperitoneal chemohyperthermia, in specialised centres, but the prognosis still remains poor (50-70% 5-year global survival rate).
  • [MeSH-major] Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731187.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 26
  •  go-up   go-down


8. Loungnarath R, Causeret S, Brigand C, Gilly FN, Glehen O: [Pseudomyxoma peritonei: new concept and new therapeutic approach]. Ann Chir; 2005 Feb;130(2):63-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomyxoma peritonei: new concept and new therapeutic approach].
  • Pseudomyxoma peritonei is a rare disease, usually diagnosed after the discover of "jelly belly" by laparotomy.
  • Pseudomyxoma peritonei need to considered as border line malignant disease because of its inevitable persistence and progression without adapted therapeutic approach: cytoreductive surgery combined with perioperative intraperitoneal chemotherapy (intraperitoneal chemohyperthermia and/or immediate postoperative intraperitoneal chemotherapy) into specialized centres.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737316.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 43
  •  go-up   go-down


9. Lepistö A, Osterlund P, Järvinen HJ: [Treatment of pseudomyxoma peritonei is developing]. Duodecim; 2010;126(14):1693-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pseudomyxoma peritonei is developing].
  • In pseudomyxoma peritonei a mucinous tumor of the appendix spreads into the abdominal cavity.
  • Cytologic picture of the tumor may be benign, malignant or intermediary.
  • This treatment is associated with a morbidity of 33 to 56% and a mortality of 0 to 18%.
  • Controlled studies have not been carried out on the novel treatment.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Appendix / pathology. Combined Modality Therapy. Disease Progression. Humans. Neoplasm Invasiveness. Therapeutic Irrigation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804088.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


10. Lam CW, Kuo SJ, Chang HC, Chen ST, Chen YL, Yang LH, Hsieh CS: Pseudomyxoma peritonei, origin from appendix: report of cases with images. Int Surg; 2003 Jul-Sep;88(3):133-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei, origin from appendix: report of cases with images.
  • This report demonstrates the cases of a 47-year-old housewife, a 54-year-old female, and an 80-year-old woman in whom pseudomyxoma peritonei was found accidentally during surgery.
  • Pseudomyxoma peritonei is a rare disease.
  • No effective treatment is known.
  • Modern treatments include radical surgical excision with appendicectomy and oophorectomy in women and adjuvant hyperthermic intraperitoneal and systemic chemotherapy.
  • Five-year survival rate, depending on whether the disease is benign or malignant, is about 53-75%.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Aged. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Female. Humans. Middle Aged. Mucocele / pathology. Mucocele / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584767.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M: Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol; 2008 Sep 15;98(4):277-82
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).
  • Pseudomyxoma peritonei (PMP) is a rare condition mostly originating from low malignant potential mucinous tumours of the appendix.
  • Recently, the combined approach of cytoreductive surgery (CRS) and perioperative loco-regional chemotherapy (PLC) has been proposed as the standard of treatment for the disease.
  • The present paper summarizes the available literature data and the main features of the comprehensive loco-regional treatment of PMP.
  • Results were presented for further evaluation during a dedicated session of "The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006)".
  • The experts agreed that multiple prospective trials support a benefit of the procedure in terms of improved survival, as compared with historical controls.
  • [MeSH-major] Appendiceal Neoplasms / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726894.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


12. Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL: Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg; 2010 Oct;211(4):526-35
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
  • BACKGROUND: Cytoreductive surgery and perioperative intraperitoneal chemotherapy (PIC) is recognized as an effective treatment modality for patients with pseudomyxoma peritonei.
  • This study investigates its role as a secondary definitive treatment procedure after earlier primary treatments.
  • STUDY DESIGN: Patients with pseudomyxoma peritonei undergoing secondary cytoreduction combined with PIC were identified from a prospective database.
  • Retrospective analysis investigated the outcomes, prognostic factors, critical time points, and impact of malignant dedifferentiation.
  • RESULTS: The median time to progression after secondary cytoreduction was 28 months (95% CI 14 to 41 months), median survival was 97 months (95% CI 82 to 113 months), and 10-year survival was 25%.
  • Requiring an urgent treatment (waiting time < 60 days) after disease progression (p = 0.045) and having moderate or severe symptoms (p = 0.033) were associated with a shorter time to progression.
  • Improved survival was associated with patients who had low-grade tumors (p = 0.029), and those who required less urgent treatment (wait > 30 days) after disease progression (waiting up to 15 days, p = 0.010; waiting up to 30 days, p = 0.005).
  • Malignant dedifferentiation appeared to affect survival from initial diagnosis (p = 0.062) and after secondary cytoreduction (p = 0.006).
  • Tumors that undergo malignant dedifferentiation appear to adversely affect survival, and this may support the rationale for early definitive treatment with cytoreduction and PIC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Cell Differentiation. Cell Transformation, Neoplastic. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Surgeons. All rights reserved.
  • [CommentIn] J Am Coll Surg. 2011 May;212(5):906; author reply 907 [21530846.001]
  • (PMID = 20729102.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Gölkel C, Widjaja A, Hiller W, Flemming P, Wagner S, Manns MP: Malignant peritoneal mesothelioma with mimicry of pseudomyxoma peritonei in a patient with a history of perforated sigmadiverticulitis. Z Gastroenterol; 2000 Apr;38(4):311-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma with mimicry of pseudomyxoma peritonei in a patient with a history of perforated sigmadiverticulitis.
  • Ultrasonography and computed tomography were suggestive of pseudomyxoma peritonei.
  • However, malignant mesothelioma peritonei was diagnosed by open surgery with biopsy for histological examination.
  • Despite R-2-resection of the tumor and following open hyperthermic intraperitoneal chemotherapy with initial remarkable recovery the patient died 5 months after therapeutical intervention.
  • Malignant peritoneal mesothelioma is an extremely rare tumor with great diagnostic and therapeutic difficulties.
  • We report a case including diagnostical work up and the medical surgical therapy of this disease.
  • [MeSH-major] Diverticulitis, Colonic / radiography. Intestinal Perforation / radiography. Mesothelioma / radiography. Peritoneal Neoplasms / radiography. Pseudomyxoma Peritonei / radiography. Sigmoid Diseases / radiography
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Hyperthermia, Induced. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820864.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


14. Elias D, Honoré C, Ciuchendéa R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goéré D: Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg; 2008 Sep;95(9):1164-71
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by progressive intraperitoneal accumulation of mucous and mucinous implants, usually derived from a ruptured, possibly malignant mucinous neoplasm of the appendix.
  • Treatment based on complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is gaining support.
  • RESULTS: Mortality (7.6 per cent) and morbidity (67.6 per cent) were significantly correlated with peritoneal index, pathological grade and blood CA19.9 level.
  • CONCLUSION: CCRS is the most effective treatment for PMP, and adding HIPEC prolongs long-term survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Injections, Intraperitoneal. Male. Organoplatinum Compounds / administration & dosage. Preoperative Care / methods. Prognosis. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690633.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Cotte E, Passot G, Isaac S, Gilly FN, Glehen O: [Malignant primary peritoneal tumors]. Presse Med; 2009 Dec;38(12):1814-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary peritoneal tumors].
  • Malignant primary peritoneal tumors are rare and should be kept in mind when peritoneal carcinomatosis is diagnosed without primary tumor found.
  • The principal etiologies are peritoneal mesthelioma, pseudomyxoma peritonei and primary peritoneal serous carcinoma.
  • Their diagnosis requires most of the time biopsy performing by laparoscopy that should prevent tumoral parietal diffusion (port sites on the middle line).
  • The treatment of reference combines optimal cytoreductive surgery and perioperative intraperitoneal chemotherapy when general status allows performing it.
  • The management of these diseases should be done into specialized centers, included into national network (RENAPE), because of specificity and complexicity of treatments and to facilitate clinical and fundamental research on rare disease.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cancer Care Facilities. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / drug therapy. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasm Staging. Peritoneum / pathology. Prognosis. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356892.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


16. Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH: Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori; 2005 Sep-Oct;91(5):394-400
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomographic characterization of malignant peritoneal mesothelioma.
  • AIMS AND BACKGROUND: Peritoneal mesothelioma is a rare disease with a universally fatal outcome when managed in a traditional palliative manner.
  • New approaches to treatment using cytoreductive surgery and intraperitoneal chemotherapy suggest that long-term survival is possible in selected patients.
  • Early recognition of this disease process with an orderly surgical approach will begin to optimize treatment.
  • METHODS: Thirty-three patients with malignant peritoneal mesothelioma had CT scans available for review.
  • CONCLUSIONS: Malignant peritoneal mesothelioma by CT evaluation predominates in tumor mass within the central and pelvic portions of the abdomen.
  • [MeSH-major] Mesothelioma / diagnostic imaging. Peritoneal Neoplasms / diagnostic imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Abdomen / pathology. Abdomen / surgery. Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Pelvis / pathology. Pelvis / surgery. Pseudomyxoma Peritonei / diagnostic imaging. Radiography, Abdominal

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459635.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Beyrouti MI, Beyrouti R, Frikha F, Ben Amar M, Abid M, Ben Ameur H, Ben Salah K, Guirat A, Boujelben S: [Peritoneal gelatinous ascites]. Presse Med; 2007 Jul-Aug;36(7-8):1141-7
Genetic Alliance. consumer health - Gelatinous Ascites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal gelatinous ascites].
  • Pseudomyxoma peritonei or gelatinous ascites is a rare clinical entity, and its pathogenesis remains obscure.
  • Ultrasonography and computed tomography provide complementary signs: septa and scalloping of the liver margins, respectively.
  • Effusion in the lesser peritoneal cavity suggests this diagnosis.
  • Recurrence is more frequent in the forms associated with malignant or bipolar tumors.
  • Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the only therapy shown to be effective in cases of recurrence or malignant forms.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Appendectomy. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperthermia, Induced. Laparotomy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / therapy. Paracentesis. Preoperative Care. Rare Diseases. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603922.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


18. Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ: Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol; 2009 Aug;16(8):2188-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
  • BACKGROUND: Cytoreductive surgery (CRS) including gastric resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the prognosis of selected patients with peritoneal surface malignancies.
  • Perioperative morbidity of this aggressive treatment strategy is high; however, overall mortality can be low in specialized centers.
  • RESULTS: Of all patients included, 16 had pseudomyxoma peritonei, 11 gastric carcinoma, 4 ovarian carcinoma, 3 malignant peritoneal mesothelioma, and 3 colon carcinoma.
  • Twenty-seven patients had previous surgery (n = 22) and/or systemic chemotherapy (n = 18).
  • Fifteen total gastrectomies, 3 subtotal gastrectomies, 12 distal gastrectomies, and 7 gastric wedge resections were performed during CRS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Hyperthermia, Induced. Neoplasms / drug therapy. Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Prognosis. Risk Factors. Safety. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408049.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol; 2009 Feb;16(2):345-51
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
  • We evaluated the perioperative safety profile and efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in 21 patients with peritoneal carcinomatosis (PC) from gastrointestinal and gynecological cancers.
  • Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- .5 degrees C for 60 to 90 minutes.
  • We analyzed the following: local and systemic infections; gastrointestinal function recovery; hematological, hepatic, and renal parameters; wound healing time; adverse events; survival; and quality of life.
  • Two patients developed generalized edema and were successfully treated.
  • Five patients developed hypoproteinemia on day 1 after surgery.
  • Time of gastric tube removal was 2 to 7 days.
  • Liquid food intake time was 3 to 8 days.
  • Time of removal of stitches was 8 to 18 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Camptothecin / administration & dosage. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mesothelioma / mortality. Mesothelioma / pathology. Mesothelioma / therapy. Middle Aged. Mitomycin / administration & dosage. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Prognosis. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Survival Rate

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018599.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Muñoz-Casares FC, Rufián S, Rubio MJ, Lizárraga E, Díaz-Iglesias C, Aranda E, Ciria R, Muntané J, Barrios P, Torres-Melero J, González-Moreno S, González-Bayón L, Camps B, Bretcha P, Farré J, Ortega-Pérez G, Gómez-Portilla A: Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol; 2007 Oct;9(10):652-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.
  • Peritoneal carcinomatosis, considered years ago as a final stage of unresectable cancer, can now be managed with curative intention by means of a radical cytoreductive surgical procedure with associated peritonectomy and intraperitoneal chemotherapy, as described by Sugarbaker.
  • Malignant neoplasms such as mesothelioma and pseudomyxoma peritonei, ovarian and colon cancer nowadays are experiencing some new therapeutical approaches.
  • Higher survival rates can be reached in ovarian cancer, which is commonly diagnosed in the presence of peritoneal carcinomatosis, using an optimal cytoreductive radical surgery with intraperitoneal chemotherapy.
  • An actualised review of the treatment of advanced ovarian cancer and a proposal of a national multicentre protocol for the treatment of peritoneal carcinomatosis from ovarian cancer has been performed by a group of Spanish surgeons and oncologists dedicated to a therapeutical approach to this pathology.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Patient Selection. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Clin North Am. 2002 May;40(3):609-36 [12117196.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):80-7 [11869020.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3019-27 [12926156.001]
  • [Cites] AJR Am J Roentgenol. 2002 Aug;179(2):391-5 [12130439.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] Hepatogastroenterology. 1994 Jun;41(3):207-13 [7959539.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):69-73 [12559080.001]
  • [Cites] J Surg Oncol. 2006 Sep 15;94(4):316-24 [16917864.001]
  • [Cites] Curr Oncol Rep. 2001 Jan;3(1):11-8 [11123864.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):120-6 [11504363.001]
  • [Cites] Acta Chir Belg. 2004 Jun;104(3):246-56 [15285533.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):571-8 [16446329.001]
  • [Cites] J Nippon Med Sch. 2000 Feb;67(1):5-8 [10777840.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):399-403 [11855877.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):146-50 [1894174.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):444-51 [15661234.001]
  • [Cites] Expert Opin Pharmacother. 2002 Jun;3(6):755-66 [12036415.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):341-5 [14599864.001]
  • [Cites] Curr Probl Surg. 1999 Jan;36(1):1-53 [9924485.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):671-5 [16621425.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):560-6 [15840878.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(2):106-14 [9923815.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:241-6 [16343239.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9 [15823105.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1589-99 [7602348.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63 [17105988.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):518-21 [15123461.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):351-6 [8636743.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Ann Surg Oncol. 2003 May;10 (4):463-8 [12734097.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):663-8 [11078613.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Bull Cancer. 2006 Jul;93(7):669-76 [16873075.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):26-30 [15449183.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Oncologist. 2002;7 Suppl 5:20-8 [12324630.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):505-15 [12241653.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1329-36 [12168946.001]
  • [Cites] Radiology. 2002 May;223(2):495-9 [11997559.001]
  • [Cites] Cancer Treat Res. 1996;81:75-87 [8834577.001]
  • [Cites] Cancer Invest. 2001;19(6):597-602 [11486702.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Radiology. 2000 Jun;215(3):761-7 [10831697.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1040-5 [15573262.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):587-92 [14675340.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):71-9 [16039699.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):825-33 [14567034.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):90-6 [17173957.001]
  • [Cites] J Med Assoc Thai. 2001 Jul;84(7):958-65 [11759976.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):310-5 [11606090.001]
  • [Cites] G Chir. 1999 Mar;20(3):81-6 [10217864.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1435-7 [9931904.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Jun;1(1):142-8 [12113122.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):181-8 [10504666.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Surg Oncol. 2005 May 1;90(2):51-6; discussion 56-8 [15844187.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):209-23 [14730047.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:208-11 [14656282.001]
  • [Cites] Curr Oncol Rep. 1999 Sep;1(1):54-8 [11122798.001]
  • [Cites] Radiology. 1992 Jan;182(1):133-8 [1727276.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] World J Surg Oncol. 2004 Jun 28;2:21 [15222884.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):147-51 [14751150.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(5):405-10 [12440812.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):25-33 [7557611.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):254-61 [9548609.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):556-61 [15762356.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):666-70 [16618534.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:74-8 [16515571.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 17974526.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] Italy
  • [Number-of-references] 83
  •  go-up   go-down


21. Georgescu S, Angheluţ A, Andronic D, Prescorniţă L, Bradea C, Crumpei F, Bălan G, Gologan E, Florea N, Ferariu D: Mucinous digestive tumors. Case reports and review of the literature. Rom J Gastroenterol; 2002 Sep;11(3):213-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present three rare entities of mucinous tumors: appendiceal mucinous adenomas, enteroid mucinous cyst and pseudomyxoma peritonei, the latter as a developmental course or separate idiopathic etiology of mucinous tumors.
  • We attempted to clarify the term of pseudomyxoma peritonei, a poorly understood condition, characterized by a diffuse intraperitoneal collection of gelatinous fluid with mucinous tumoral implants on the peritoneal surfaces.
  • With this rare condition it is often difficult to establish the histological and developmental malignant or benign characteristics.
  • In three of the four patients the diagnosis was possible preoperatively by imaging techniques and consequently they were operated by laparoscopic procedure for the complete removal of tumor cells at macroscopic level.
  • We preferred to administrate chemotherapy accordingly to the malignant/ benign aspect, choosing the long term follow up of the patients to ward off the eventual relapse.
  • This methodology also allows different surgery for a different pathology at the same time.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / therapy. Digestive System Neoplasms / diagnosis. Digestive System Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12368941.001).
  • [ISSN] 1221-4167
  • [Journal-full-title] Romanian journal of gastroenterology
  • [ISO-abbreviation] Rom J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 13
  •  go-up   go-down


22. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol; 2003 Oct;129(10):549-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
  • PURPOSE: To perform a phase I study of intraperitoneal cis-bis-neodecanoato ( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles (L-NDDP) for peritoneal carcinomatosis or sarcomatosis.
  • Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration.
  • Afterwards, chemotherapy was administered through a peritoneal catheter.
  • Peritoneal imaging with technetium-labeled sulfur colloid was used to determine adequate distribution prior to each course.
  • Diagnoses were: malignant mesothelioma (six patients), signet ring cell (three), colon adenocarcinoma, pseudomyxoma peritonei, gastrointestinal stromal tumor (two each), and ovarian carcinoma (one).
  • Peri-operative complications included one colonic perforation requiring primary closure, a peritoneal catheter malfunction, a port site hematoma, and an ascites leak requiring re-suture.
  • Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment.
  • Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.
  • CONCLUSIONS: Peritoneal cavity exposure to L-NDDP is prolonged, and systemic absorption is limited, yielding a high peritoneal/plasmatic ratio.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Organoplatinum Compounds / pharmacokinetics. Peritoneal Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adult. Aged. Area Under Curve. Ascites / metabolism. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / metabolism. Female. Humans. Injections, Intraperitoneal. Liposomes. Male. Mesothelioma / drug therapy. Mesothelioma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Peritoneum / diagnostic imaging. Peritoneum / metabolism. Radionuclide Imaging. Technetium. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4509-12 [3396003.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):315-7 [1879050.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58 [8202717.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503 [12107555.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] J Med Chem. 1991 Jan;34(1):325-9 [1992134.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):131-42 [417410.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):21-6 [3039867.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):1-8 [2720887.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8 [4048973.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):323-9 [8458256.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4254-9 [2364384.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3944-6 [12351590.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):65-71 [2104572.001]
  • (PMID = 14513369.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II); 7440-26-8 / Technetium
  •  go-up   go-down






Advertisement